Literature DB >> 8085690

Interpreting HIV serodiagnostic test results in the 1990s: social risks of HIV vaccine studies in uninfected volunteers. NIAID AIDS Vaccine Clinical Trials Group.

R B Belshe1, M L Clements, M C Keefer, B S Graham, L Corey, R Sposto, S Wescott, D Lawrence.   

Abstract

OBJECTIVE: To evaluate the influence of a human immunodeficiency virus (HIV) vaccine given to uninfected volunteers on the interpretation of serodiagnostic HIV test results.
DESIGN: Retrospective cohort study.
SETTING: 5 AIDS Vaccine Evaluation Units funded by the National Institute of Allergy and Infectious Diseases. PARTICIPANTS: The first 266 healthy adult volunteers (aged 18 to 60 years) who did not have HIV infection and whose history suggested that they were at low risk for acquiring HIV infection. MEASUREMENTS: HIV antibody was measured by enzyme-linked immunosorbent assay (ELISA) and Western blot test, the results of which were interpreted on the basis of four different published criteria.
RESULTS: At some time during the first 12 months of the vaccine studies, 68% of volunteers were positive for HIV antibodies by ELISA. Depending on criteria used to interpret Western blot test results, 0% to 44% of volunteers had positive results that might have caused them to be incorrectly labeled as HIV infected.
CONCLUSIONS: Significant social risks to volunteers participating in HIV vaccine studies were identified. Persons interpreting HIV serodiagnostic test results must consider that an HIV vaccine can cause a positive result in persons who are not infected.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8085690     DOI: 10.7326/0003-4819-121-8-199410150-00005

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  3 in total

1.  Performance of a redesigned HIV Selectest enzyme-linked immunosorbent assay optimized to minimize vaccine-induced seropositivity in HIV vaccine trial participants.

Authors:  Oksana Penezina; Neil X Krueger; Isaac R Rodriguez-Chavez; Michael P Busch; John Hural; Jerome H Kim; Robert J O'Connell; Eric Hunter; Said Aboud; Keith Higgins; Victor Kovalenko; David Clapham; David Crane; Andrew E Levin
Journal:  Clin Vaccine Immunol       Date:  2014-01-08

2.  Social Impacts Among Participants in HIV Vaccine Trial Network (HVTN) Preventive HIV Vaccine Trials.

Authors:  Michele P Andrasik; Fredericka Albertina Sesay; Abby Isaacs; Linda Oseso; Mary Allen
Journal:  J Acquir Immune Defic Syndr       Date:  2020-08-15       Impact factor: 3.731

3.  Human immunodeficiency virus (HIV) vaccine trials: a novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies.

Authors:  Surender Khurana; James Needham; Bonnie Mathieson; Isaac R Rodriguez-Chavez; Andrew T Catanzaro; Robert T Bailer; Jerome Kim; Vicky Polonis; David A Cooper; Jan Guerin; Michael L Peterson; Marc Gurwith; Nga Nguyen; Barney S Graham; Hana Golding
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.